MA54944A - Combinaisons de fractions de liaison se liant à egfr, her2 et her3 - Google Patents

Combinaisons de fractions de liaison se liant à egfr, her2 et her3

Info

Publication number
MA54944A
MA54944A MA054944A MA54944A MA54944A MA 54944 A MA54944 A MA 54944A MA 054944 A MA054944 A MA 054944A MA 54944 A MA54944 A MA 54944A MA 54944 A MA54944 A MA 54944A
Authority
MA
Morocco
Prior art keywords
binding
her3
her2
egfr
combinations
Prior art date
Application number
MA054944A
Other languages
English (en)
Inventor
Kruif Cornelis Adriaan De
Tristan Louis Jean Gallenne
Cecilia Anna Wilhelmina Geuijen
Mark Throsby
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of MA54944A publication Critical patent/MA54944A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054944A 2019-02-14 2020-02-13 Combinaisons de fractions de liaison se liant à egfr, her2 et her3 MA54944A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157302 2019-02-14
EP19178564 2019-06-05

Publications (1)

Publication Number Publication Date
MA54944A true MA54944A (fr) 2021-12-22

Family

ID=69771003

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054944A MA54944A (fr) 2019-02-14 2020-02-13 Combinaisons de fractions de liaison se liant à egfr, her2 et her3

Country Status (13)

Country Link
US (1) US20220127376A1 (fr)
EP (1) EP3924384A1 (fr)
JP (2) JP2022520649A (fr)
KR (1) KR20210126703A (fr)
AU (1) AU2020222749A1 (fr)
BR (1) BR112021016094A2 (fr)
CA (1) CA3130248A1 (fr)
IL (1) IL285490A (fr)
MA (1) MA54944A (fr)
MX (1) MX2021009768A (fr)
SG (1) SG11202108737RA (fr)
TW (1) TW202045541A (fr)
WO (1) WO2020167123A1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027236A2 (fr) 2006-08-30 2008-03-06 Genentech, Inc. Anticorps multispécifiques
CN105191863B (zh) 2008-06-27 2020-12-22 莫鲁斯股份有限公司 产生抗体的非人哺乳动物
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
EP2635604B1 (fr) * 2010-11-01 2016-11-30 Symphogen A/S Composition d'antcorps pan-her
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
CA2872226A1 (fr) * 2012-05-02 2013-11-07 Symphogen A/S Compositions d'anticorps pan-her humanises
RU2014149681A (ru) * 2012-05-24 2016-07-20 Ф. Хоффманн-Ля Рош Аг Антитела с множественной специфичностью
CA2941030A1 (fr) * 2014-02-28 2015-09-03 Merus N.V. Anticorps qui se lient a l'egfr et a l'erbb3
CN106459212B (zh) * 2014-02-28 2021-07-13 美勒斯公司 结合erbb-2和erbb-3的抗体
EP4050026A1 (fr) * 2014-04-01 2022-08-31 Adimab, LLC Procédé d'obtention ou d'identification d'une ou plusieurs chaînes légères communes à utiliser dans la préparation d'un anticorps multispécifique
AU2015313811A1 (en) * 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)

Also Published As

Publication number Publication date
EP3924384A1 (fr) 2021-12-22
IL285490A (en) 2021-09-30
BR112021016094A2 (pt) 2021-10-26
MX2021009768A (es) 2021-09-08
TW202045541A (zh) 2020-12-16
JP2024023598A (ja) 2024-02-21
KR20210126703A (ko) 2021-10-20
WO2020167123A1 (fr) 2020-08-20
US20220127376A1 (en) 2022-04-28
JP2022520649A (ja) 2022-03-31
CA3130248A1 (fr) 2020-08-20
AU2020222749A1 (en) 2021-09-02
SG11202108737RA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
BR112016025056A2 (pt) uso de pelo menos um polipeptídeo, anticorpo biespecífico, anticorpo biespecífico isolado, anticorpo her3/her2 biespecífico, célula hospedeira, método de produção do anticorpo biespecífico her3/her2, imunoconjugado e formulação farmacêutica
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
MA41669A1 (fr) Anticorps se liant a tau
BR112017003194B8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
MA45680A (fr) Protéines de liaison bispécifiques de type anticorps se liant spécifiquement à cd3 et cd123
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
BR112014027291A2 (pt) composições de anticorpos pan-her humanizados
EA202091315A3 (ru) Антитела человека, связывающиеся с g-белком rsv
DK3325514T3 (da) Her2-bindende proteiner baseret på di-ubiquitin-muteiner
DK3645571T3 (da) Her3-antigen-bindende molekyler
CL2017002705A1 (es) Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren
BR112019013468A8 (pt) Anticorpos anti-hiv-1 amplamente neutralizante e métodos de uso dos mesmos
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
MX2017012775A (es) Preparacion combinatoria de anticuerpos anti-staphylococcus aureus.
BR112018002319A2 (pt) anticorpos anti-cd154 e métodos de uso dos mesmos
DK3253785T3 (da) Hidtil ukendte egfr-bindingsproteiner
CR20150195A (es) Proteínas ligantes de antígeno anti-her3/her4 de unión a la horquilla beta de her3 y la horquilla beta de her4
BR112015012708A2 (pt) anticorpos para bmp-6
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
BR112017020610A2 (pt) Compostos de anticorpo biespecífico anti-dkk-1- anti-rankl
MA49289A (fr) Anticorps se liant à steap-1